Isatuximab
Sarclisa (isatuximab) is an antibody pharmaceutical. Isatuximab was first approved as Sarclisa on 2020-03-02. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
| Trade Name | Sarclisa |
|---|---|
| Common Name | Isatuximab |
| Indication | multiple myeloma |
| Drug Class | Monoclonal antibodies: chimeric, tumors as target |
